These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 31632140)

  • 21. The Prognostic Value of the Novel Global Immune-Nutrition-Inflammation Index (GINI) in Stage IIIC Non-Small Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy.
    Topkan E; Selek U; Pehlivan B; Kucuk A; Ozturk D; Ozdemir BS; Besen AA; Mertsoylu H
    Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760482
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic Significance of ¹⁸F-FDG Uptake in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization or Concurrent Chemoradiotherapy: A Multicenter Retrospective Cohort Study.
    Lee JW; Oh JK; Chung YA; Na SJ; Hyun SH; Hong IK; Eo JS; Song BI; Kim TS; Kim DY; Kim SU; Moon DH; Lee JD; Yun M
    J Nucl Med; 2016 Apr; 57(4):509-16. PubMed ID: 26742711
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pretreatment Masseter Muscle Volume Predicts Survival in Locally Advanced Nasopharyngeal Carcinoma Patients Treated with Concurrent Chemoradiotherapy.
    Pehlivan UA; Somay E; Yilmaz B; Besen AA; Mertsoylu H; Selek U; Topkan E
    J Clin Med; 2023 Oct; 12(21):. PubMed ID: 37959329
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systemic immune-inflammation index changes predict outcome in stage III non-small-cell lung cancer patients treated with concurrent chemoradiotherapy.
    Huang T; Zhang H; Zhao Y; Li Y; Wang G; Zhang Y; Guo D; Ji S; Sun Z
    Future Oncol; 2021 Jun; 17(17):2141-2149. PubMed ID: 33635094
    [No Abstract]   [Full Text] [Related]  

  • 25. Five-year survival rate analysis: the combination of fortnightly-administration of endostar and concurrent chemoradiotherapy versus concurrent chemoradiotherapy in the treatment of inoperable locally advanced non-small cell lung cancer.
    Ma H; Peng F; Xu Y; Bao Y; Hu X; Wang J; Fang M; Kong Y; Dong B; Chen M
    Ann Palliat Med; 2021 Jul; 10(7):7560-7570. PubMed ID: 34353044
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low Prognostic Nutritional Index Predicts Poor Clinical Outcomes in Patients with Stage IIIB Non-small-cell Lung Carcinoma Undergoing Chemoradiotherapy.
    Ozdemir Y; Topkan E; Mertsoylu H; Selek U
    Cancer Manag Res; 2020; 12():1959-1967. PubMed ID: 32214853
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Nutrition-Related Factor-Based Risk Stratification for Exploring the Clinical Benefits in the Treatment of Patients With Locally Advanced Esophageal Squamous Cell Carcinoma Receiving Definitive Chemoradiotherapy: A Retrospective Cohort Study.
    Yu Y; Wu H; Qiu J; Ke D; Wu Y; Lin M; Liu T; Zheng Q; Zheng H; Yang J; Wang Z; Li H; Liu L; Yao Q; Li J; Cheng W; Chen X
    Front Nutr; 2022; 9():896847. PubMed ID: 35990358
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcomes and prognostic factors in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy.
    Liu J; Tang G; Zhou Q; Kuang W
    Radiat Oncol; 2022 Aug; 17(1):142. PubMed ID: 35978412
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Significance of overall concurrent chemoradiotherapy duration on survival outcomes of stage IIIB/C non-small-cell lung carcinoma patients: Analysis of 956 patients.
    Topkan E; Ozdemir Y; Kucuk A; Besen AA; Mertsoylu H; Sezer A; Selek U
    PLoS One; 2019; 14(7):e0218627. PubMed ID: 31329602
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nomograms for predicting prognostic value of combined neutrophil-to-lymphocyte ratio and SCC-Ag in locally advanced cervical cancer.
    Jin L; Cao F; Zhang Y; Dang Y; Wang F
    Transl Cancer Res; 2024 Mar; 13(3):1323-1335. PubMed ID: 38617514
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Change in carbohydrate antigen 19-9 level as a prognostic marker of overall survival in locally advanced pancreatic cancer treated with concurrent chemoradiotherapy.
    Kim YJ; Koh HK; Chie EK; Oh DY; Bang YJ; Nam EM; Kim K
    Int J Clin Oncol; 2017 Dec; 22(6):1069-1075. PubMed ID: 28477059
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early Change in Metabolic Tumor Heterogeneity during Chemoradiotherapy and Its Prognostic Value for Patients with Locally Advanced Non-Small Cell Lung Cancer.
    Dong X; Sun X; Sun L; Maxim PG; Xing L; Huang Y; Li W; Wan H; Zhao X; Xing L; Yu J
    PLoS One; 2016; 11(6):e0157836. PubMed ID: 27322376
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic efficacy of the combination of the pretreatment systemic Immune-Inflammation Index and Epstein-Barr virus DNA status in locally advanced Nasopharyngeal Carcinoma Patients.
    Xiong Y; Shi LL; Zhu LS; Ding Q; Ba L; Peng G
    J Cancer; 2021; 12(8):2275-2284. PubMed ID: 33758605
    [No Abstract]   [Full Text] [Related]  

  • 34. Consolidative Chemoradiotherapy After Induced Chemotherapy Is an Optimal Regimen for Locally Advanced Pancreatic Cancer.
    Wu L; Zhou Y; Fan Y; Rao S; Ji Y; Sun J; Li T; Du S; Guo X; Zeng Z; Lou W
    Front Oncol; 2019; 9():1543. PubMed ID: 32039019
    [No Abstract]   [Full Text] [Related]  

  • 35. The value of the Advanced Lung Cancer Inflammation Index (ALI) in assessing the prognosis of patients with hepatocellular carcinoma treated with camrelizumab: a retrospective cohort study.
    Li Q; Ma F; Tsilimigras DI; Åberg F; Wang JF
    Ann Transl Med; 2022 Nov; 10(22):1233. PubMed ID: 36544677
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Feasibility and efficiency of concurrent chemoradiotherapy with a single agent or double agents vs radiotherapy alone for elderly patients with esophageal squamous cell carcinoma: Experience of two centers.
    Huang C; Zhu Y; Li Q; Zhang W; Liu H; Zhang W; Hu Y; Yuan Y; Liu M
    Cancer Med; 2019 Jan; 8(1):28-39. PubMed ID: 30600600
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictive value of metabolic 18FDG-PET response on outcomes in patients with locally advanced pancreatic carcinoma treated with definitive concurrent chemoradiotherapy.
    Topkan E; Parlak C; Kotek A; Yapar AF; Pehlivan B
    BMC Gastroenterol; 2011 Nov; 11():123. PubMed ID: 22074002
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intensity modulated radiotherapy for locally advanced and metastatic pancreatic cancer: a mono-institutional retrospective analysis.
    Wang Z; Ren ZG; Ma NY; Zhao JD; Zhang Z; Ma XJ; Long J; Xu J; Jiang GL
    Radiat Oncol; 2015 Jan; 10():14. PubMed ID: 25575617
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Influence of Systemic Inflammation Response Index on Survival Outcomes of Limited-Stage Small-Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy.
    Kucuk A; Ozkan EE; Eskici Oztep S; Mertsoylu H; Pehlivan B; Selek U; Topkan E
    J Oncol; 2020; 2020():8832145. PubMed ID: 33381177
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Paraneoplastic thrombocytosis independently predicts poor prognosis in patients with locally advanced pancreatic cancer.
    Chadha AS; Kocak-Uzel E; Das P; Minsky BD; Delclos ME; Mahmood U; Guha S; Ahmad M; Varadhachary GR; Javle M; Katz MH; Fleming JB; Wolff RA; Crane CH; Krishnan S
    Acta Oncol; 2015 Jul; 54(7):971-8. PubMed ID: 25608822
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.